Request Demo

Last update 27 Feb 2026

Bexarotene

Last update 27 Feb 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid, 4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid, Bexarotene (JAN/USAN/INN)

+ [21]

Target

RXRs

Action

agonists, inhibitors

Mechanism

RXRs agonists(Retinoid X receptor agonists), Protein synthesis inhibitors

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [5]

Active Indication

Cutaneous T-Cell LymphomaCushing SyndromeEsophageal Squamous Cell Carcinoma+ [2]

Inactive Indication

Advanced breast cancerAdvanced Lung Non-Small Cell CarcinomaAIDS-related Kaposi Sarcoma+ [8]

Originator Organization

Ligand Pharmaceuticals, Inc.

Active Organization

HAC Pharma SASU

Minophagen Pharmaceutical Co. Ltd.

Shenzhen Main Luck Pharmaceuticals, Inc.

+ [4]

Inactive Organization

Ligand Pharmaceuticals, Inc.

Eisai, Inc.Bausch Health Ireland Ltd.

License Organization

Ewopharma AG

Ligand Pharmaceuticals, Inc.

Eisai Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

United States (29 Dec 1999),

Cutaneous T-Cell Lymphoma

RegulationOrphan Drug (United States), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC24H28O2

InChIKeyNAVMQTYZDKMPEU-UHFFFAOYSA-N

CAS Registry153559-49-0

Clinical Trials associated with Bexarotene

CTR20243921

/ RecruitingPhase 3

贝沙罗汀胶囊单药治疗既往接受至少一次全身治疗的复发或难治性皮肤T细胞淋巴瘤的开放、单臂、多中心临床试验

[Translation] An open, single-arm, multicenter clinical trial of bexarotene capsules as a monotherapy for relapsed or refractory cutaneous T-cell lymphoma who have received at least one previous systemic therapy

主要目的：在皮肤T细胞淋巴瘤(CTCL)中国人群中评价贝沙罗汀胶囊单药治疗既往接受至少一次全身治疗的复发或难治性皮肤T细胞淋巴瘤患者的有效性和安全性。次要目的：在CTCL中国人群中进行贝沙罗汀胶囊300mg/m2/d的药代动力学研究。

[Translation]

Primary objective: To evaluate the efficacy and safety of bexarotene capsules as a monotherapy in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who have received at least one previous systemic therapy in the Chinese population with cutaneous T-cell lymphoma (CTCL). Secondary objective: To conduct a pharmacokinetic study of bexarotene capsules 300 mg/m2/d in the Chinese population with CTCL.

Start Date18 Feb 2025

Sponsor / Collaborator

Bushu Pharmaceuticals Ltd.

[+3]

NCT05106192

/ WithdrawnNot ApplicableIIT

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

A study to compare pain differences between using MedJet needle-free drug-delivery system with standard of care treatment for cutaneous T-cell lymphomas and cutaneous B-cell lymphomas in participants.

Start Date01 Apr 2022

Sponsor / Collaborator

The Case Comprehensive Cancer Center

NCT05296304

/ RecruitingPhase 1IIT

A Phase Ib Trial Combining Bexarotene With Ultra-Low Dose Total Skin Electron Beam (Tseb) Radiotherapy For The Treatment Of Diffuse Cutaneous T-Cell Lymphomas

The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF).
Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. TSEB radiotherapy is a type of radiation therapy that treats the entire surface of the skin with very low doses of radiation to kill cancer cells and shrink tumors. This type of radiation does not pass through the outer layers of the skin into the tissues and organs below the skin.
The study researchers think that giving bexarotene treatment at the same time as treatment with TSEB radiotherapy may be more effective against MF than either treatment given alone or in sequence (one after the other).

Start Date16 Mar 2022

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

100 Clinical Results associated with Bexarotene

100 Translational Medicine associated with Bexarotene

100 Patents (Medical) associated with Bexarotene

1,167

Literatures (Medical) associated with Bexarotene

01 Feb 2026·AQUATIC TOXICOLOGY

Toxicity of tetrachlorobisphenol A interfering with craniofacial cartilage development by inhibiting RXR activity in zebrafish

Article

Author: Lu, Huiqiang ; Guo, Jun ; Chen, Xiaomei ; Zhong, Yinliang ; Yang, Jian ; Zhu, Hanyi

Tetrachlorobisphenol A (TCBPA), a prevalent halogenated flame retardant detected in human serum and breast milk, poses significant exposure risks during developmental windows. While recognized for reproductive toxicity, its impact on craniofacial development remains unexplored. This study investigated the effects of TCBPA (0.5, 0.6, and 0.7 mg/L) on zebrafish cartilage development during craniofacial bone development (11-96 h post-fertilization). At experimental concentrations, TCBPA induced a range of developmental issues, notably significant craniofacial deformities, which were characterized by abnormal specifications and morphology of Meckel's and ceratohyal cartilages. Additionally, qPCR results revealed that TCBPA exposure led to the down-regulation of genes related to cartilage development. Moreover, it antagonized retinoid X receptor subtype beta-a (RXRba), a key receptor in the retinoic acid (RA) signaling pathway, leading to suppressed expression of downstream target genes essential for cartilage development. TUNEL staining further demonstrated that TCBPA exposure triggered excessive apoptosis of zebrafish craniofacial chondrocytes, a finding corroborated by qPCR results indicating altered expression of apoptosis-related genes. This phenomenon may be attributed to the collaborative involvement of RXRs and peroxisome proliferator-activated receptor gamma (PPARγ) in regulating cell survival, differentiation, and apoptosis. The antagonism of TCBPA on RXRba was also validated in a rescue experiment using Bexarotene, a high affinity agonist of RXRs. In conclusion, TCBPA inhibits the expression of genes crucial to cartilage development by antagonizing RXRba activity. It also induces abnormal apoptosis of chondrocytes through other signaling pathways mediated by RXRs, resulting in craniofacial cartilage toxicity in zebrafish.

01 Feb 2026·BIOMEDICINE & PHARMACOTHERAPY

Potential effects of bexarotene on neural development and function in zebrafish embryos

Article

Author: Meng, Yunlong ; Zhong, Zilin ; Liu, Kangyu ; Wang, Minglei ; Huang, Lirong ; Xie, Yuanhai ; Du, Jiayi ; Song, Mingxia ; Cao, Zigang ; Li, Haining ; Zha, Wenwen ; Chen, Jianjun ; Yin, Nan

Bexarotene is a retinoid X receptor (RXR) agonist that plays a crucial role in cell growth and differentiation. It has shown potential in treating both early- and late-stage cutaneous T-cell lymphoma (CTCL). However, the impact of Bexarotene on the neurodevelopment of aquatic organisms, particularly aquatic vertebrates, remains poorly understood. This study aimed to investigate the effects of various concentrations of bexarotene (3 μg/L, 6 μg/L, and 9 μg/L) on the development of the zebrafish embryonic nervous system, using zebrafish as a model organism. The underlying molecular mechanisms were explored through a combination of pharmacological interventions, molecular biology, histopathology, and transcriptomics. Studies have shown that zebrafish embryos exposed to Bex show significant changes in development, including morphological abnormalities, head malformations, significantly shortened head length and width, reduced fluorescent area, cell apoptosis, shortened spinal motor neuron axon length, abnormal myelin development, decreased oligodendrocytes, cerebellar developmental damage, and abnormal behavior. Transcriptomics and qPCR results showed abnormal expression of neurodevelopmental genes (olig2, mbpa, atoh1a, gfap, ngn1, gap43, etc.). In addition, exposure to medium and high concentrations of bexarotene significantly increased acetylcholinesterase (AChE) activity. Bexarotene activates the Wnt signaling pathway, and treatment with the Wnt inhibitor IWR-1 can partially rescue the neurodevelopmental impairments in embryos. In summary, bexarotene offers new insights into the potential neurodevelopmental risks in zebrafish embryos, emphasizing the importance of preventing drug side effects and ensuring the safe and rational use of medications to protect the health of living organisms.

01 Feb 2026·FREE RADICAL BIOLOGY AND MEDICINE

Activation of RXRα mitigates maternal separation-induced hippocampal neurodevelopmental impairment in mice by inhibiting oxidative stress and restoring mitochondrial homeostasis

Article

Author: Tang, Daowei ; Li, Jianhong ; Wei, Haidong ; Zang, Ziye ; Zhang, Shijie ; Liu, Yuanyuan ; Xing, Lu ; Yang, Senyue

Adverse events in early life can alter the developmental trajectory of glial cells and neurons in the brain, increasing an individual's risk of developing neuropsychiatric disorders later in life. Retinoid X receptor alpha (RXRα), a member of the nuclear receptor superfamily, has been shown to exert protective effects on the central nervous system when activated. However, whether RXRα plays a role in maternal separation (MS) and the underlying mechanisms remain unclear. In this study, we used MS in BALB/c mice to simulate early-life stress, aiming to investigate the impact of MS on hippocampal neuronal development in mice during early life, as well as the neuroprotective role of RXRα and its mechanisms. The results showed that MS induced hippocampal neuronal damage and inhibited RXRα expression in offspring mice. In contrast, RXRα activation significantly ameliorated hippocampal neuronal damage in MS mice and exerted neuroprotective effects by suppressing oxidative stress, repairing mitochondrial dysfunction, reducing neuronal apoptosis, and promoting mitophagy. Further analysis revealed that bexarotene (an RXR agonist) exerted neuroprotective effects by upregulating the expression levels of RXRα and peroxisome proliferator-activated receptor gamma (PPARγ). In HT22 cells with hydrogen peroxide (H₂O₂)-induced damage, knockdown of PPARγ expression via small interfering RNA (siRNA) significantly attenuated the neuroprotective effect of RXRα activation against neuronal damage. In conclusion, MS impairs the development of hippocampal neurons in offspring mice, which may alter the developmental trajectory of the nervous system and increase the risk of neuropsychiatric disorders in adulthood. Activation of RXRα can effectively alleviate oxidative stress and neuronal damage in the hippocampus by improving mitochondrial dysfunction. Therefore, targeting RXRα holds promise as a potential strategy for treating the consequences of early-life trauma.

News (Medical) associated with Bexarotene

31 Jul 2024

·www.fiercehealthcare.com

Wells Fargo relationship with Express Scripts under scrutiny in new lawsuit

Wells Fargo joins Johnson & Johnson as the most recent company sued over employee prescription drug price management. Wells Fargo is the most recent corporation to get sued, as alleged by former employees, for inadequately overseeing the price workers were forced to pay for prescription drug prices.In a class action lawsuit filed in federal court named Navarro et al v. Wells Fargo Company, employees say the company did not fulfill its fiduciary obligations. Under the Employee Retirement Income Security Act of 1974, employers are required to adequately manage employee benefits programs.The plaintiffs argue Wells Fargo’s management of the prescription drugs program resulted in higher premiums, out-of-pocket costs and limited wage growth because of the prices it agreed to pay Express Scripts, one of its pharmacy benefit managers, for generic drugs.Employees, they say in the suit, were forced to pay nearly $10,000 for a a prescription of fingolimod, used to treat multiple sclerosis, when the generic version could be purchased without insurance for less than a $1,000 at pharmacies like Cost Plus Drugs and Rite Aid. “No prudent fiduciary would agree to make its plan and participants/beneficiaries pay a price that is fifteen times higher than the price available to anyone who just walks into a pharmacy and pays without using their insurance,” the plaintiffs said in the lawsuit.Across approximately 300 generic drugs, Wells Fargo and Express Scripts made employees pay a markup on average of 114.97% what it costs pharmacies to obtain the drugs, the lawsuit alleges. For specialty drugs, employees said they paid a markup of 383% on average.Other prescriptions were far more expensive for employees at Express Scripts’ pharmacy Accredo. Bexarotene gel, available at Rite Aid for $3,750, cost employees nearly $70,000 from Accredo.“The price discrepancies noted herein are illustrative of a pervasive and systematic problem of unreasonable prescription drug charges, despite well-known alternatives available to defendants,” the lawsuit said. Plaintiffs in the lawsuit say Wells Fargo should have received better rates from Express Scripts or a different PBM, guided employees to more cost-effective options or utilized a pass-through PBM that doesn’t use spread pricing.Wells Fargo was also tagged with accusations that it should have operated with more expertise given its standing in the industry. Plaintiffs noted Wells Fargo publishes research on the economics of the pharma industry, hosts an annual healthcare conference with speakers from major PBMs, operates an employee benefits consulting practice and has publicly warned about rising prescription drug costs and business practices by Express Scripts.A similar lawsuit was filed against Johnson & Johnson in February by the same law firm, Fairmark Partners.“This case alleges that Wells Fargo has failed its employees once again, this time by agreeing to obviously unreasonable terms and prices with its PBM that cause workers to vastly overpay for prescription drugs,” said Michael Lieberman, an attorney with Fairmark Partners. “After years of scrutiny and with clear alternatives available, there are no excuses left for a large corporation like Wells Fargo to ignore its legal obligation to identify reasonable prescription drug coverage options for its employees.” Mark Cuban, founder of Cost Plus Drugs, said in a X post that this type of lawsuit can be expected to occur more often.“This lawsuit is going to happen over and over and over with self insured companies until they realize they have to drop their big 3 PBM and use a Pass Through PBM,” he said. “The good news is if they switch they will save money and get control of their claims data.”As well as the Wells Fargo health plan, top human resource employees were also named as defendants in the lawsuit.Wells Fargo and Express Scripts did not immediately respond to a request for comment from Fierce Healthcare.Aon, the broker for Wells Fargo, was also listed in the lawsuit. Express Scripts was not listed as a defendant.

Patent Infringement

26 Oct 2023

·www.prnewswire.com

SciTech Development Announces The Formation of a Distinguished Medical Advisory Board With Top Oncology Specialists

GROSSE POINTE FARMS, Mich., Oct. 26, 2023 /PRNewswire/ -- SciTech Development, LLC, today announced the formation of a distinguished and independent medical advisory board (MAB) comprised of key opinion leaders and world-renowned experts in T-Cell Lymphomas and hematological malignancies. The board will provide strategic and clinical advice for SciTech's outreach and education initiatives within the oncology community. Continue Reading SciTech Medical Advisory Board "SciTech is excited and incredibly proud that this world-class group of medical experts will assist us with innovative insights that enable us to bring ST-001 to patients who have limited options in their cancer treatments," said President and Managing Partner Earle Holsapple. "The clarity they bring in understanding the clinical needs of patients will serve to guide us through the commencement of our phase 1 clinical trial and through our subsequent expedited clinical program." The three medical advisors appointed to the board are Madeleine Duvic, M.D., Larisa Geskin, M.D., and Ajay Gopal, M.D. Madeleine Duvic, MD – "The development of ST-100 is exciting because this new drug holds the promise of improved bioavailability, leading to increased efficacy with low toxicity." Dr. Duvic is a Professor of Medicine and Dermatology practices in Houston, Texas, and holds the Blanche Bender Endowed Chair of Research. Her clinical research includes translational/molecular studies leading to improved therapies for cutaneous T-cell lymphomas. She has written over 500 peer-reviewed papers and a book on Retinoids. She participated in the development of topical and oral tazarotene and bexarotene which both received FDA approval. Larisa J. Geskin, MD, FAAD - "I am thrilled to support SciTech's innovative approach to cancer therapeutics. SciTech's patented nanoparticle platform, SDP, enhances the effectiveness and safety of fenretinide, which has shown promise in treating patients with incurable cutaneous lymphomas in preliminary studies. SciTech's flagship product, ST-001, stands out for its ability to deliver therapeutic doses without toxic side effects, greatly benefiting our patients." Dr. Geskin is a Professor of Dermatology (in Medicine, Division of Hematology-Oncology) at Columbia University Medical Center and the Director of the Comprehensive Cutaneous Oncology Center at the Columbia University Department of Dermatology. Dr. Geskin serves as the Immediate Past-President of the International Society for Cutaneous Lymphomas (ISCL), the Secretary-Treasurer of the US Cutaneous Lymphomas Consortium (USCLC), and the Founding Chair of the New York Cutaneous Lymphoma Consortium (NYCLC), among her many other responsibilities. Ajay K. Gopal, MD - "Based on the encouraging preclinical data from a variety of laboratories, our observed tolerability of fenretinide, and the unmet need in a spectrum of malignancies novel formulations such as ST-001 nanoFenretinide are certainly worthy of further investigation." Dr. Gopal received his undergraduate degree from Duke University and his MD from Emory University. He completed his internal medicine training at Duke University School of Medicine and his oncology training at the University of Washington and Fred Hutchinson Cancer Center, where he currently holds an endowed chair and serves as a Professor and Clinical Research Director for Hematologic Malignancies. Dr. Gopal has over 2 decades of experience in the development of novel therapies for lymphoma, as reflected by over 200 publications in the field, including the first translational and clinical trial data evaluating fenretinide in lymphoma. Contact: Earle Holsapple Email: [email protected] About SciTech Development SciTech Development, LLC is a clinical-stage pharmaceutical company that has developed a patented nanoparticle drug delivery platform (SDP) that maximizes the bioavailability of water-insoluble therapeutics. SciTech's lead drug candidate, ST-001 nanoFenretinide, combines SDP and the drug fenretinide as a new drug product with potentially broad effectiveness in many cancers. For more information about the Company, please visit: SOURCE SciTech Development

Phase 1Executive Change

17 Nov 2022

·medcitynews.com

Two Pharmacy Owners Plead Guilty in $18M Foreign Medicare Fraud Scheme

Two New York pharmacy owners who “exploited the Covid-19 emergency for their own financial gain,” pleaded guilty to an international scheme to submit fraudulent claims to Medicare for cancer medication, the Department of Justice announced Wednesday. Arkadiy Khaimov, 39, of Forest Hills, and Peter Khaim, 42, also of Forest Hills, engaged in an elaborate healthcare scheme involving more than a dozen pharmacies in New York, according to the justice department. The two would submit millions of dollars in fraudulent Medicare claims for expensive cancer drugs that were not prescribed or distributed to patients. The drugs, Targretin gel, made by Bausch and Panretin gel, made by Concordia, were allegedly dispensed during periods when certain pharmacies were closed due to the pandemic. “Khaim, Khaimov, and their co-conspirators exploited the Covid-19 emergency for their own financial gain by using COVID-19-related ‘emergency override’ billing codes to submit additional fraudulent claims for Targretin Gel 1%,” the justice department said in a news release. The scheme started in New York but became a complex international endeavor as the two men attempted to launder money, amounting to more than $18 million. Khaim and Khaimov established shell companies and sham pharmacy wholesale companies to create the illusion they were operating actual businesses. In reality, they were sending funds from the false Medicare claims to the sham companies. Then, the funds were sent to companies in China and distributed to individuals in Uzbekistan. At that point, the two men received some of the funds in cash, the announcement said. They also allegedly sent money from the fraudulent claims to their relatives through cashier’s checks and used the money themselves to purchase property. Both men face a 20-year prison sentence and their separate hearings are scheduled for May 2023. A spokeperson for the Center for Medicare and Medicaid Services did not immediately respond to a request for comment.

Patent Infringement

100 Deals associated with Bexarotene

External Link

KEGG	Wiki	ATC	Drug Bank
D03106	Bexarotene	L01XX25	DB00307

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cutaneous T-Cell Lymphoma	United States	Dr. Jean Bausch GmbH & Co. KG	29 Dec 1999
Cutaneous T-Cell Lymphoma	United States	Bausch Health Ireland Ltd.	29 Dec 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alopecia Areata	Phase 3	United States	Ligand Pharmaceuticals, Inc.	01 May 2003
metastatic non-small cell lung cancer	Phase 3	United States	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	Austria	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	Canada	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	France	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	Germany	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	Spain	Eisai, Inc.	01 May 2002
Non-Small Cell Lung Cancer	Phase 3	United States	Eisai, Inc.	01 May 2002
Non-Small Cell Lung Cancer	Phase 3	Austria	Eisai, Inc.	01 May 2002
Non-Small Cell Lung Cancer	Phase 3	Canada	Eisai, Inc.	01 May 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


TCL-213 (SOHO2023)	Not Applicable	Peripheral T-Cell Lymphoma	-	Bexarotene 150 mg/m^2	uynapcuymu(dguxrjmpuz) = The most common toxicities were hypothyroidism and hyperlipidemia and effectively managed khcnyayrjk (nyqyzsoygt ) View more	Positive	01 Sep 2023
NCT03323658 (CTgov)	Phase 1	Breast Ductal Carcinoma \| Breast Carcinoma in Situ \| Atypical Lobular Breast Hyperplasia ... View more	24	Bexarotene (Dose Level 1)	srrzkzajwi = bjiktjidjq hleadbjony (osetgznbse, pdsodcetlk - litiywcjsi) View more	-	06 Dec 2022
NCT03323658 (CTgov)	Phase 1		24	Bexarotene (Dose Level 2)	srrzkzajwi = rttcrbgopw hleadbjony (osetgznbse, cajivtdqbo - snoptbjmiv) View more	-	06 Dec 2022
ISRCTN14265371 (CCMR One, ECTRIMS2021)	Phase 2	-	31	Bexarotene	fwsstustsw(whcfbaiwjo) = significant adverse events were observed on the trial aojdixnkdv (qvwklnpqfy )	Positive	12 Oct 2021
ISRCTN14265371 (CCMR One, ECTRIMS2021)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	52	Bexarotene	lkovnebnrv(yqgwmxzsoj) = geyojaejjr gecandgges (dymyktdrur ) View more	-	12 Oct 2021
ISRCTN14265371 (CCMR One, ECTRIMS2021)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	52	Placebo	lkovnebnrv(yqgwmxzsoj) = hfkrlmzelm gecandgges (dymyktdrur ) View more	-	12 Oct 2021
CCMR-One (ECTRIMS2020)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	52	Bexarotene 300mg/m2	vkhvjypvmx(lzkuznwlef) = 100% of bexarotene patients experienced central hypothyroidism crfckchxvw (ozvtjuwtxa ) View more	Positive	07 Dec 2020
CCMR-One (ECTRIMS2020)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	52	Placebo		Positive	07 Dec 2020
NCT00615784 (UPCC04407, CTgov)	Phase 2	Acute Myeloid Leukemia	24	Bexarotene	hxkjvojnht = rznrdqrnsm xfzgsharcu (rrnfktxjmd, pmlriyrgfc - vormazteot) View more	-	17 Nov 2020
NCT01007448 (CTgov)	Phase 4	Cutaneous T-Cell Lymphoma	59	Bexarotene	vqeceyofyn = iunvuyaxtt ydbpbfguyc (eondghfixz, hnbctepwdd - skorjrbvyg) View more	-	12 Nov 2019
NCT00153842 (CTgov)	Phase 1/2	Advanced Lung Non-Small Cell Carcinoma	33	Paclitaxel+Carboplatin+Bexarotene (Phase IB: Bexarotene 300mg, Paclitaxel and Carboplatin)	ggtgxbbdrn = umlorcxwxi tlohqytptd (hsqstdmirs, itwiusqodh - qvqpdjpwsp)	-	06 Mar 2019
NCT00153842 (CTgov)	Phase 1/2	Advanced Lung Non-Small Cell Carcinoma	33	Paclitaxel+Carboplatin+Bexarotene (Phase IB: Bexarotene 400mg, Paclitaxel and Carboplatin)	ggtgxbbdrn = ezxkgprhzp tlohqytptd (hsqstdmirs, ozmoeerhty - bsqlddtoyh)	-	06 Mar 2019
NCT00125359 (CTgov)	Phase 2	Advanced Lung Non-Small Cell Carcinoma	42	Erlotinib+Bexarotene	tknyasuwfg = ndewgogzwb tbwuiqajev (mztbnabdkg, ubzjqjlqwh - xdnhaexkuu) View more	-	13 Nov 2018
NCT00125372 (CTgov)	Not Applicable	Resectable Lung Non-Small Cell Carcinoma	12	Tarceva+Targretin	helcquppgo = ivnpqrokfv pofpstvgpr (ubykvmgzqc, jgasmpysdm - ldzdsjkpfk) View more	-	13 Nov 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis